BOOK NOW TO SAVE $500

July 24-26, 2018
Boston, USA

www.ai-clinicaldevelopment.com

AI PHARMA INNOVATION CLINICAL DEVELOPMENT

Driving the real world applications of AI & machine learning for clinical trials and precision medicine

Expert Speakers Including:

Raj Bandaru
Senior Director, Data Sciences Strategy, Translational Informatics
Sanofi

Alex Zhavoronkov
CEO
InSilico Medicine

Haoda Fu
Research Advisor & Enterprise Lead for Machine Learning and Artificial Intelligence Group
Eli Lilly

Gregory V. Goldmacher
Executive Director, Translational Biomarkers
Merck

Arun Asaithambi
CEO
Lantern Pharma

Shanrong Zhao
Director, Computational Biology- Worldwide Research & Development
Pfizer

Edward Bowen
Head of Data Science & Solutions
GSK

Ray Liu
Senior Director & Head, Advanced Analytics & Statistical Consultation
Takeda

Leonardo Rodrigues
Senior Director, AI & Machine Learning
Berg

Sponsors

medidata enlitic indico

Tel: +1 617 455 4188 Email: info@hansonwade.com AI Application in Pharma

hansonwade

AI Pharma Innovation: Clinical Development Summit 2018

Effectively Integrate & Apply AI & Machine Learning to Improve & Accelerate Your Clinical Trial Success

Optimizing Trial Design and Improving Patient Selection to Deliver More Effective, Value-Based & Precision Medicines to Market

The AI Pharma Innovation: Clinical Development Summit will bring together the leading scientists, technology developers, & key decision makers in the pharmaceutical and biotechnology industries.

As part of the AI Pharma Innovation Series 2018, the only set of conferences solely dedicated to accelerating the effective adoption and successful application of AI and machine learning technologies at specific points of the pharmaceutical value chain, join the AI Pharma Innovation: Clinical Development Summit to discover how to harness AI to enhance trial design, improve patient selection, identify biomarkers for precision medicine development and optimize pharmacovigilance studies.

As clinical failure rates remain unsustainable, the inaugural AI Pharma Innovation: Clinical Development Summit is committed to help large pharma, biotech and artificial intelligence innovators overcome key strategic and technical challenges of integrating the right AI solution and applying it specifically to maximize and accelerate clinical development and regulatory success.

What experts are looking forward to at this summit

"Looking forward to networking and potential collaboration"

Jie Cheng- Associate Director, Data & Statistical Sciences- **Abbvie**

"This summit, is a great opportunity to bridge industry with high-end academic research"

Christos Papadelis- Head, Laboratory of Children's Brain Dynamics; Assistant Professor of Pediatrics- **Harvard Medical School**



Why Attend AI Pharma Innovation: Clinical Development Summit 2018?

1.

Understand how AI & machine learning is disrupting the current approach to clinical development through case studies from **GSK, Merck, Sanofi** & **Abbvie**



2.

Assessing and addressing key challenges and opportunities of real world applications of AI & machine learning in clinical development based on case studies from **Merck, Pfizer, GSK** & **Sanofi**



3.

Evaluating the hurdles and the future landscape of AI-driven patient stratification, biomarker identification & optimization of clinical designs based on solution led talks of leading biotechs such as **InSilico Medicine, Berg** & **Lantern Pharma**



4.

Find out about the most innovative approaches of the large pharma towards precision medicine from leaders such as **Eli Lilly** & **Abbvie**

5.

Through deep discussions with key decision makers in the industry such as **Takeda, Merck** & **Sanofi** cut through theories and learn about proof of concept of how AI is going to revolutionize traditional pharmaceutical practices

Your Expert Speakers

Alex Zhavoronkov
CEO
InSilico Medicine

Joseph Lehar
Executive Director, Computational Biology, MRL
Merck

Haoda Fu
Research Advisor & Enterprise Lead for Machine Learning and Artificial Intelligence Group
Eli Lilly

Jie Cheng
Associate Director, Data & Statistical Sciences
Abbvie

Ruthie Davi
Director, Data Science
Medidata Solutions

Ray Liu
Senior Director & Head, Advanced Analytics & Statistical Consultation
Takeda

Arun Asaithambi
CEO
Lantern Pharma

Gregory V. Goldmacher
Executive Director, Translational Biomarkers
Merck

Raj Bandaru
Senior Director, Data Sciences Strategy, Translational Informatics
Sanofi

Shanrong Zhao
Director, Computational Biology- Worldwide Research & Development
Pfizer



Edward Bowen
Head of Data Science & Solutions
GSK

Leonardo Rodrigues
Senior Director, AI & Machine Learning
Berg

Ronald Dorenbos
Associate Director, Materials & Innovation
Takeda

Amy Zwanziger
Head, Digital Catalyst
Sanofi

Christos Papadelis
Head, Laboratory of Children's Brain Dynamics; Assistant Professor of Pediatrics
Harvard Medical School

Sehyo Yune
Director of Research Translation, Laboratory of Medical Imaging & Computation
Massachusetts General Hospital

Sean Grullon
Machine Learning Data Scientist
GSK

Vladimir Morozov
Bioinformatics Solutions Architect
Shire Pharmaceuticals

WHY ARE OUR EXPERT SPEAKERS LOOKING FORWARD TO THE SUMMIT?

"Networking, sharing Sanofi's message and helping to build partner implementation capabilities"

Amy Zwanziger- Head, Digital Catalyst- Sanofi

"Interested in brainstorming and learning from peers"

Shanrong Zhao- Director, Computational Biology- Worldwide Research & Development- Pfizer

"Looking forward to network with industry peers and get to know the service providers"

Ray Liu- Senior Director & Head, Advanced Analytics & Statistical Consultation- Takeda

"As a thought leader in AI drug development, look forward to both learning and guiding pharma"

Arun Asaithambi- CEO- Lantern

"GSK is striving to be a thought leader in Machine Learning and Artificial Intelligence in the Pharma space, and it is valuable to us to share with and learn from other thought leaders in this space"

Sean Grullon- Machine Learning Data Scientist- GSK

"To engage in the timely discussion about the use of AI in the pharmaceutical industry and network with key players in the field"

Sehyo Yune- Director of Research Translation, Laboratory of Medical Imaging & Computation- Massachusetts General Hospital

Conference Day One | Wednesday, 25 July, 2018

8.00 Registration & Breakfast

8.50 Chair's Opening Remarks

Robust Translation from Discovery to Clinic & Early Clinical Design

Introduction and Purpose:

The ultimate goal of researchers is to translate scientific findings into practical clinical applications. Despite successful pre-clinical testing, the majority of early clinical trials for novel drugs fail and of those that survive through to phase III only half become approved for clinical use. AI & machine learning have the potential to assist researchers and clinicians to achieve successful translation and ultimately reduce clinical trial failure rates.

Alex Zhavoronkov
CEO
InSilico Medicine

9.00 Case Study: GANs'n'Roses: GANs Generating De Novo Molecular Structures with Experimental Validation

- The deep-neural networks (DNN) are being successfully applied for de novo design of drug-like lead compounds that have the higher probability of success in clinical trials due to the prediction of appropriate physicochemical properties for specific targets
- The Adversarial Threshold Neural Computer (ATNC) based on generative adversarial network (GAN) architecture and reinforcement learning (RL) has shown the high efficiency in the generating of drug-likeness properties for novel small organic molecules
- In vitro validation of the molecules generated by ATNC confirmed that ATNC is an effective method for producing hit compounds

Shanrong Zhao
Director, Computational Biology- Worldwide Research & Development
Pfizer

9.30 Case Study: Dimensional Reduction of RNA-Seq Data by Deep Learning and Its Application to Explore Cell Transition

- Advantages and disadvantages of different dimensional reduction methods
- Dimension reduction by deep variational autoencoder
- Application to explore cell transition among different subset of innate lymphoid cells

Sean Grullon
Machine Learning Data Scientist
GSK

10.00 Case Study: Using Machine Learning to Analyze Clinical Trials that Fail to Meet Primary Endpoints

- Factors that cause clinical trials to fail their primary endpoints can be difficult to uncover with traditional statistical methods. Modern Machine Learning techniques can discover features which cause the primary endpoints to fail in historical clinical trial data
- Machine Learning methods can scale longitudinally across studies and seamlessly handle a large number of covariates
- Insights on features that drive primary endpoint failure can be used to inform better clinical trial study design in the future

10.30 Speed Networking & Morning Refreshments

Matching AI & Machine Learning Benefits to Pharma Challenges in Clinical Development

Introduction and Purpose:

Failed clinical trials result in wasted money and resources, lost jobs and a setback in research. The financial pain of trial failure will eventually encourage pharma to change its approach and processes to be more efficient and successful in the long term. While the use of AI in clinical development is still limited, identifying, addressing and overcoming the pitfalls and opportunities associated with its real world applications are the enabler to the success of AI in drug development.

Haoda Fu
Research Advisor & Enterprise Lead for Machine Learning and Artificial Intelligence Group
Eli Lilly

11.30 Case Study: The Future is Now– The Most Promising Areas of AI/ Machine Learning for Pharmaceutical Industry

- There are growing interests on AI for clinical development, pitfalls and opportunities co-exist. Where are the real opportunities?
- Through years and extensive evaluations, we have identified 4 areas which are tangible and have potential significant impacts on drug development
- Successful examples will be provided and potential next steps will be discussed

Arun Asaithambi
CEO
Lantern Pharma

12.00 Case Study: Pharma's Holy Grail: How to Solve the Right Patient Stratification Problem?

- Improving the success of traditional drug development
- The right types of datasets
- Lantern Pharma Approach: A Specific AI Application Technology

Amy Zwanziger
Head, Digital Catalyst
Sanofi

12.30 Case Study: Real talk: 5 Ways to Succeed with Big Pharma

- What are the common themes of successful AI partners? What are the most common mistakes?
- What are the unique challenges of partnering with big pharma?
- What is Sanofi's approach to digital partnerships?

13.00 Networking Lunch

Moving from Theory into Practice by Implementation of AI in Clinical Development

14.00 Discuss: Real World/Pragmatic Clinical Trials and the Use of AI to Design & Monitor Them

- How to leverage AI as an informatics tool to inform whether drugs work as well in the real world as they did in clinical trials?
- How AI could help with choosing patients that are true representation of the population?
- What are the limitations of monitoring an AI-driven pragmatic clinical trial and how to over come them?

Moderator:

Shanrong Zhao
Director, Computational Biology- Worldwide Research & Development
Pfizer

Faculty:

Ray Liu
Senior Director & Head, Advanced Analytics & Statistical Consultation
Takeda

Joseph Lehar
Executive Director, Computational Biology, MRL
Merck

Edward Bowen
Head of Data Science & Solutions
GSK

Leonardo Rodrigues
Senior Director, AI & Machine Learning
Berg

14.45 Case Study: Applying AI-Driven Approaches to Improve Clinical Development Efficiency

- Reviewing the need to implement AI in Clinical Development
- Discussing the key points necessary to deploy a functional AI-guided clinical trial
- Demonstrating how AI can de-risk clinical development by stratifying patients based on selected outcomes

15.15 Afternoon Refreshments & Networking

15.45 Roundtable Discussions:

Our breakout roundtables will allow you to have more intimate discussions with AI and pharma leaders around some of the hottest topics in the field. Discover multiple perspectives on these key issues, so that you can learn from your fellow experts in the audience. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself in the following discussions:

Discussion Leader

Ruthie Davi
Director, Data Science
Medidata Solutions

1. Mitigating Go/No-Go decision risks through reusing historical trial data and advanced analytics

Co- Leaders

Rishi Karvir
Senior Manager of Predictive Modeling
Medidata Solutions

Lisa Ensign
Senior Lead Biostatistician
Medidata Solutions

2. Improve patient enrollment through predictive modeling

3. Using machine learning to improve trial efficiency

16.45 Chair's Closing Remarks & End of Day One

"Promising new conference that I am looking forward to attending again"

Marko Zivkovic- CSO- Genesis Research

Conference Day Two | Thursday, 26 July, 2018

8.30 **Breakfast & Networking**

8.50 **Chair's Opening Remarks**

Applying AI to Make Precision Medicine a Reality: The Intelligent Trial

Introduction and Purpose:

Slowly but surely, AI technologies are revolutionizing health care and advancing the clinical trial process. Cutting costs, improving trial quality, and reducing trial times by almost half are some of the promising potentials of an AI-driven clinical trial. Furthermore, as a disruptive technology, AI is an opportunity to precision medicine as it can deeply investigate the roots of diseases and treatments and move the industry away form its current "one-size-fits-all" strategy.

Jie Cheng
Associate Director, Data & Statistical Sciences
Abbvie

9.00 **Case Study: Machine Learning Based Patient Subgroup Identification for Precision Medicine**

- What is patient subgroup identification?
- What are the challenges and how machine learning can help?
- How to incorporate patient subgroup identification in clinical development?

Ronald Dorenbos
Associate Director, Materials & Innovation
Takeda

9.30 **Case Study: How to Maximise the Benefits of Integrating AI in Clinical Trials to Improve Recruitment Efficiency**

- Better adherence = better clinical trials
- Connecting the dots faster, better & smarter

Gregory V. Goldmacher
Executive Director, Translational Biomarkers
Merck

10.00 **Case Study: The Application of Machine Learning to the Development of Novel Imaging Biomarkers**

- AI can be used to create novel biomarkers from routine clinical scans
- Valuable AI tools can be built using historical trial data
- Data sharing and collaboration obstacles must be overcome

Raj Bandaru
Senior Director, Data Sciences Strategy, Translational Informatics
Sanofi

10.30 **Case Study: The Application of Machine Learning Approaches for Enabling Translational Medicine**

- Application of machine learning approaches to understand patient journey, predict outcomes and elucidate biological mechanisms driving certain outcome and adverse events
- The Use of patient electronic health records to explore advanced analytical methods
- Developing the appropriate models for trial simulations requires access to a wide range of data from historical studies and patient health records
- A showcase of our effort in Bayesian learning approaches to find and integrate historical clinical data in real time as well as our elastic computing platform development

11.00 **Morning Refreshments & Networking**

Current & Future Approaches to Real World Applications of AI

Introduction and Purpose:

The promise is that AI systems will deliver easily accessible, less expensive and higher quality care to patients while allowing for efficient data capturing with direct involvement of not just the clinicians but the patients themselves. Hence, further emphasising on the importance of not only optimization of candidate selection for clinical trials but also the pressing need for effective and practical connection between patients, clinicians and drug developers.

Christos Papadelis
Head, Laboratory of Children's Brain Dynamics; Assistant Professor of Pediatrics
Harvard Medical School

11.30 Case Study: Innovative Biomarkers in the Presurgical Evaluation of Children with Epilepsy

- High frequency oscillations recorded invasively and noninvasively are promising interictal biomarker of epileptogenicity
- AI can boost the development of epilepsy biomarker through training in large datasets from many epilepsy centres
- Development of sensitive and specific epilepsy biomarker can dramatically improve the surgical outcome in patients with epilepsy

Vladimir Morozov
Bioinformatics Solutions Architect
Shire Pharmaceuticals

12.00 Case Study: Application of Deep Neural Networks for Developing Digital Biomarkers from Speech and Accelerometer Data

- Deep learning enables development of biomarkers from raw sensor data without labour intensive signal analysis
- The obtained biomarkers are competitive with hand-crafted ones
- Data augmentation is critical

Sehyo Yune
Director of Research Translation, Laboratory of Medical Imaging & Computation
Massachusetts General Hospital

12.30 Case Study: AI for Connecting Patients, Clinicians, and Pharmaceuticals in Clinical Trials

- Understanding stakeholder motivations
- Capabilities and limitations of AI in the clinical trial setting
- The low-hanging fruits and the holy grail

13.00 Networking Lunch

Zooming the Spot Light on the Critical Issues: Voice, Exchange & Evaluate Ideas

14.00 Discuss: How AI & Machine Learning Could Present an Opportunity to Lower the Failure Rates of Clinical Trials Compared to the Contemporary Approaches?

- What is the impact of AI on traditional drug development?
- What is the regulatory and Commercialization outlooks of potential AI-developed drugs?
- What is the impact of AI to clinically develop "value-based" therapies?

Moderator:
TBC

Faculty:

Gregory V. Goldmacher
Executive Director, Translational Biomarkers
Merck

Arun Asaithambi
CEO
Lantern Pharma

Ronald Dorenbos
Associate Director, Materials & Innovation
Takeda

14.45 Discuss: The Application of AI & Machine Learning in Clinical Development Requires Large Amounts of Quality Data: How to Develop the Best Model of Practices in Terms of Data Access and Sharing Amongst the Industry?

- What datasets are readily available for AI application in clinical development and what are the "low-hanging fruits"?
- How to aggregate health data in a secure, trusted and automated style using AI & machine learning to benefit clinical research?
- How practical is it to form comprehensive data partnership networks amongst the leading pharma and biotech companies and what is the way forward?

Moderator:

Jie Cheng
Associate Director, Data & Statistical Sciences
Abbvie

Faculty:

Leonardo Rodrigues
Senior Director, AI & Machine Learning
Berg

Raj Bandaru
Senior Director, Data Sciences Strategy, Translational Informatics
Sanofi

15.30 Chair's Closing Remarks & Close of Inaugural AI Pharma Innovation: Clinical Development Summit 2018

"I had a really good opportunity to interact with every participant at this conference. The "Discuss" sessions and the Speed networking were an essential component of this meeting, which cannot be replaced by "virtual" conferences or webinars."

Tudor Oprea- Professor of Medicine & Chief of Translational Informatics & Internal Medicine- University of New Mexico



Pre-Conference Workshops | Tuesday, 24 July, 2018

Workshop A

AI in Discovery to Clinic: A Workshop on Strategies & Applications

10:00am – 12:30pm

This interactive workshop session delivered to you by one of the thought leaders of the industry will delve deep into multiple cutting edge models and algorithms that have shown very promising outcomes in support of applications of AI & machine learning in drug discovery and addresses a robust path for successful AI-driven drug discovery translation into clinical development.

- The several DNN-based methods have been proposed for molecular de novo design and molecular feature extraction
- The Generative Adversarial Networks (GANs) are being applied for molecular feature extraction using the fingerprint or string (in formats like SMILES or InChi) representation of molecular structure
- The DNN-models based on GANs extended with a Reinforcement Learning (RL)-based generator could generate valid SMILES string, however the adding of objective reward function is needed to reward the generator for the whole molecular sequence
- The using of different objective reward functions in Objective-Reinforced Generative Adversarial Network for Inverse-design Chemistry (ORGANIC) makes possible to generate molecules with desired user-specified properties
- The novel Adversarial Threshold Neural Computer (ATNC) architecture including a specific adversarial threshold (AT) block and using Differentiable Neural Computer (DNC) as generator outperforms the ORGANIC model in generating the valid and unique molecular structures in SMILES representation

Workshop Leader
Alex Zhavoronkov
CEO
InSilico Medicine

Workshop B

Artificial Intelligence, Machine Learning, and Precision Medicine: Colliding Technology & Science to Improve Personalized Patient Outcomes

13:30pm - 16:00pm

The pharma industry is investing in AI & machine learning technologies as the drug development paradigm shifts towards more effective, value-based & precision medicines. This case study based, solution led workshop delivered to you by one of the leading experts of the industry will provide an overview of statistical machine learning, and AI techniques with applications to the precision medicine, in particular to deriving optimal individualized treatment strategies for precision medicine. This short course will cover both treatment selection and treatment transition.

- Artificial Intelligence, Machine Learning, and Precision Medicine: Colliding Technology & Science to Improve Personalized Patient Outcomes
- An overview of statistical machine learning, and artificial intelligence techniques with applications to the precision medicine, in particular to deriving optimal individualized treatment strategies for precision medicine
- Covering both treatment selection and treatment transition. The treatment selection framework is based on outcome weighted classification
- A deep-delve into logistic regression, support vector machine (SVM), robust SVM, and angle based classifiers for multi-category learning as well as showcasing how to modify these classification methods into outcome weighted learning algorithms for precision medicine
- An introduction on reinforcement learning techniques for the purpose of treatment transition
- Algorithms, including dynamic programming for Markov Decision Process, temporal difference learning, SARSA, Q-Learning algorithms, actor-critic methods, will be covered followed by a discussion on how to use these methods for developing optimal treatment transition strategies. The techniques discussed will be demonstrated in R

Workshop Leader
Haoda Fu
Research Advisor & Enterprise Lead for Machine Learning and Artificial Intelligence Group
Eli Lilly

WHO WILL YOU MEET?

60+ ATTENDEES

6+ HOURS OF DEDICATED NETWORKING

2 INTERACTIVE WORKSHOPS

15+ REAL WORLD CASE STUDIES

PARTNERS

medidata

Roundtable Partner

Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments.

www.mdsol.com

enlitic

Brand Partner

Enlitic uses deep learning to instill actionable insights from the billions of clinical data points comprising medical images and unstructured and structured texts. We work with hospitals and pharmaceuticals to develop state-of-the-art tools to improve the efficiency and accuracy of medical data interpretation. From enhancing patient identification to improving response evaluation, as well as exploring novel imaging biomarkers, Enlitic's algorithms are being applied to optimize every stage of the clinical trial. Join us as we revolutionize health data.

www.enlitic.com

WHY SPONSOR

Benefit from Market Intelligence
Hear how and where pharmaceutical giants are looking to adopt and apply AI, enabling to match your solutions accordingly.

Position Yourself as an Industry Thought Leader
Pharma doors are now open to the idea of integrating AI programs. At this juncture it is crucial to stand out from the crowd. Demonstrate your expertise through podium presentations, moderating panel discussions or interactive roundtables.

Raise Brand Awareness
Benefit from pre and post conference exposure to our AI community and increase market share through unique branding formats.

Meet and Network with Industry Pioneers
With a room full of drug developers looking to see how they can effectively apply AI solutions, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions.

Generate Commercial Collaborations
Make sure your hottest prospects are in the room and part of the discussion, by having a wish-list of your choice contacted in advance of the event.

indico

Event Partner

Indico is an Enterprise AI solution for unstructured content. For the pharmaceutical vertical, our platform enables customers to extract valuable insights from content sources such as electronic health records, caretaker notes and regulatory documentation to aid in the identification, selection and retention of clinical trial patients.

www.indico.io

GET INVOLVED

James Woodcock
Commercial Director - AI Pharma Innovation Event Series
Tel: +44 (0) 20 3141 8739
Email: james.woodcock@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

Tel: +1 617 455 4188

Email: register@hansonwade.com

www.ai-clinicaldevelopment.com/register

1. Understand how AI & machine learning is disrupting the current approach to clinical development
2. Evaluate the hurdles and the future landscape of AI-driven patient stratification, biomarker identification & optimization of clinical designs based on solution led talks delivered by leading biotech and large pharma companies
3. Find out about the most innovative approaches of the large pharma towards AI-driven precision medicine

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

SECURE YOUR PLACE

Package Details	Register & Pay before 25 May 2018 (Save $500!)	Standard Prices
GOLD Conference + 2 Workshops	$2,299	$2,799
SILVER Conference + 1 Workshop	$2,798	$3,298
BRONZE Conference Only	$3,297	$3,797
Workshop Only	$599	
2 Workshops	$998 **(SAVE $200)**	

*Special 40% off for academics available upon request

VENUE

The Revere Hotel
200 Stuart Street,
Boston, Massachusetts 02116

For further information or assistance, please visit www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 8149